GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline plans to divest non-core OTC brands this year as CEO describes 2010 as a challenging year.
You may also be interested in...
Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.
Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.
Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
GlaxoSmithKline and Tolerx announced March 11 that their humanized anti-CD3 monoclonal antibody, otelixizumab failed to meet the primary endpoint in the Phase III DEFEND-1 trial for type 1 diabetes, and they were halting recruitment and dosing in another Phase III trial, DEFEND-2, while they review the DEFEND-1 results.